PriceTargets.com logo

Xilio Therapeutics - XLO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.10 As of 04/22/2024 01:00 AM ET
▼ -0.05 (-4.35%)

This chart shows the closing price for XLO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Xilio Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for XLO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for XLO

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Xilio Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.10.

This chart shows the closing price for XLO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Xilio Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/23/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/22/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/10/2023Chardan CapitalReiterated RatingBuyLow
1/27/2023Morgan StanleyLower TargetOverweight$20.00 ➝ $10.00Low
12/21/2022Chardan CapitalInitiated CoverageBuy$7.00Low
11/15/2022GuggenheimLower Target$15.00Low
11/10/2022Raymond JamesLower TargetOutperform$31.00 ➝ $13.00Low
8/10/2022Morgan StanleyLower TargetOverweight$32.00 ➝ $20.00Low
1/10/2022HC WainwrightInitiated CoverageBuyMedium
11/16/2021GuggenheimInitiated CoverageBuyHigh
11/16/2021Raymond JamesInitiated CoverageOutperform$31.00High
11/16/2021Morgan StanleyInitiated CoverageOverweight$32.00High
11/16/2021CowenInitiated CoverageOutperformHigh
(Data available from 4/23/2019 forward)

News Sentiment Rating

0.71 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
9/25/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/25/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/24/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/24/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
2/22/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/23/2024
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/22/2024

Current Sentiment

  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Xilio Therapeutics logo
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors. The company also develops cytokine programs, which comprises XTX202, a tumor-activated IL-2; and XTX301, an investigational tumor-activated, engineered IL-12 molecule. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $1.10
Low: $1.05
High: $1.18

50 Day Range

MA: $0.89
Low: $0.55
High: $1.53

52 Week Range

Now: $1.10
Low: $0.49
High: $3.40

Volume

254,313 shs

Average Volume

1,062,721 shs

Market Capitalization

$37.92 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Xilio Therapeutics?

The following Wall Street research analysts have issued research reports on Xilio Therapeutics in the last twelve months: Chardan Capital.
View the latest analyst ratings for XLO.

What is the current price target for Xilio Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Xilio Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Xilio Therapeutics in the next year.
View the latest price targets for XLO.

What is the current consensus analyst rating for Xilio Therapeutics?

Xilio Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe XLO will outperform the market and that investors should add to their positions of Xilio Therapeutics.
View the latest ratings for XLO.

What other companies compete with Xilio Therapeutics?

Other companies that are similar to Xilio Therapeutics include Nabriva Therapeutics, Aadi Bioscience, NextCure, Bolt Biotherapeutics and Rockwell Medical. Learn More about companies similar to Xilio Therapeutics.

How do I contact Xilio Therapeutics' investor relations team?

The company's listed phone number is 857-524-2466 and its investor relations email address is [email protected]. The official website for Xilio Therapeutics is www.xiliotx.com. Learn More about contacing Xilio Therapeutics investor relations.